Effects of myricetin on the bioavailability of carvedilol in rats

References

• Abshagen U. (1987). A new molecule with vasodilating and beta-adrenoceptor blocking properties. J Cardiovasc Pharmacol, 10 Suppl 11, S23–S32.
   Google Scholar
• Bart J, Dijkers EC, Wegman TD, de Vries EG, van der Graaf WT, Groen HJ, Vaalburg W, Willemsen AT, Hendrikse NH. (2005). New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br J Pharmacol, 145, 1045–1051.
   PubMed Web of Science ®Google Scholar
• Benet LZ, Cummins CL, Wu CY. (2003). Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab, 4, 393–398.
   PubMed Web of Science ®Google Scholar
• Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res, 23, 1675–1686.
   PubMed Web of Science ®Google Scholar
• Cournot A, Lim C, Duchier J, Safar M. (1992). Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. J Cardiovasc Pharmacol, 19 Suppl 1, S35–S39.
   Google Scholar
• Crespi CL, Miller VP, Penman BW. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem, 248, 188–190.
   PubMed Web of Science ®Google Scholar
• Cummins CL, Jacobsen W, Benet LZ. (2002). Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther, 300, 1036–1045.
   PubMed Web of Science ®Google Scholar
• DasGupta P, Broadhurst P, Lahiri A. (1991). The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure. J Cardiovasc Pharmacol, 18 Suppl 4, S12–S16.
   Google Scholar
• Dixon RA, Steele CL. (1999). Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trends Plant Sci, 4, 394–400.
   PubMed Web of Science ®Google Scholar
• Frishman WH. (1998). Carvedilol. N Engl J Med, 339, 1759–1765.
   PubMed Web of Science ®Google Scholar
• Häkkinen SH, Kärenlampi SO, Heinonen IM, Mykkänen HM, Törrönen AR. (1999). Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem, 47, 2274–2279.
   PubMed Web of Science ®Google Scholar
• Hampton JR. (1996). Beta-blockers in heart failure–the evidence from clinical trials. Eur Heart J, 17 Suppl B, 17–20.
   PubMedGoogle Scholar
• Han CY, Cho KB, Choi HS, Han HK, Kang KW. (2008). Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis, 29, 1837–1844.
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Fasco MJ. (1991). Small intestinal cytochromes P450. Crit Rev Toxicol, 21, 407–422.
   PubMed Web of Science ®Google Scholar
• Kitagawa S, Nabekura T, Takahashi T, Nakamura Y, Sakamoto H, Tano H, Hirai M, Tsukahara G. (2005). Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull, 28, 2274–2278.
   PubMed Web of Science ®Google Scholar
• Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. (1992). Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest, 90, 1871–1878.
   PubMed Web of Science ®Google Scholar
• Lewis DFV. (1996). Cytochromes P450: Structure, Function and Mechanism. Bristol, England, Taylor & Francis Publisher and Distributor.
   Google Scholar
• Lund-Johansen P, Omvik P, Nordrehaug JE, White W. (1992). Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. J Cardiovasc Pharmacol, 19 Suppl 1, S27–S34.
   PubMed Web of Science ®Google Scholar
• McTavish D, Campoli-Richards D, Sorkin EM. (1993). Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs, 45, 232–258.
   PubMed Web of Science ®Google Scholar
• Morgan T. (1994). Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet, 26, 335–346.
   PubMed Web of Science ®Google Scholar
• Neugebauer G, Akpan W, von Möllendorff E, Neubert P, Reiff K. (1987). Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol, 10 Suppl 11, S85–S88.
   PubMedGoogle Scholar
• Neugebauer G, Neubert P. (1991). Metabolism of carvedilol in man. Eur J Drug Metab Pharmacokinet, 16, 257–260.
   PubMed Web of Science ®Google Scholar
• Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. (2001). Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr, 74, 418–425.
   PubMed Web of Science ®Google Scholar
• Nishijima CM, Rodrigues CM, Silva MA, Lopes-Ferreira M, Vilegas W, Hiruma-Lima CA. (2009). Anti-hemorrhagic activity of four Brazilian vegetable species against Bothrops jararaca venom. Molecules, 14, 1072–1080.
   PubMed Web of Science ®Google Scholar
• Oldham HG, Clarke SE. (1997). In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos, 25, 970–977.
   PubMed Web of Science ®Google Scholar
• Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. (1993). P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett, 324, 99–102.
   PubMed Web of Science ®Google Scholar
• Tiwari R, Mohan M, Kasture S, Maxia A, Ballero M. (2009). Cardioprotective potential of myricetin in isoproterenol-induced myocardial infarction in Wistar rats. Phytother Res, 23, 1361–1366.
   PubMedGoogle Scholar
• Václavíková R, Horský S, Simek P, Gut I. (2003). Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch Pharmacol, 368, 200–209.
   PubMed Web of Science ®Google Scholar
• von Möllendorff E, Abshagen U, Akpan W, Neugebauer G, Schröter E. (1986). Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. Clin Pharmacol Ther, 39, 677–682.
   PubMedGoogle Scholar
• von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ. (2004). Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol, 56, 1039–1044.
   PubMed Web of Science ®Google Scholar
• Xue B, Li J, Chai Q, Liu Z, Chen L. (2008). Effect of total flavonoid fraction of Astragalus complanatus R. Brown on angiotensin II-induced portal-vein contraction in hypertensive rats. Phytomedicine, 15, 759–762.
   PubMed Web of Science ®Google Scholar
• Zarghi A, Foroutan SM, Shafaati A, Khoddam A. (2007). Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. J Pharm Biomed Anal, 44, 250–253.
   PubMed Web of Science ®Google Scholar